RU2012105641A - Фолатнацеленные диагностические средства и лечение - Google Patents
Фолатнацеленные диагностические средства и лечение Download PDFInfo
- Publication number
- RU2012105641A RU2012105641A RU2012105641/15A RU2012105641A RU2012105641A RU 2012105641 A RU2012105641 A RU 2012105641A RU 2012105641/15 A RU2012105641/15 A RU 2012105641/15A RU 2012105641 A RU2012105641 A RU 2012105641A RU 2012105641 A RU2012105641 A RU 2012105641A
- Authority
- RU
- Russia
- Prior art keywords
- tumor
- patient
- administering
- folate receptors
- clinical benefit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- G01N33/5752—
-
- G01N33/57545—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23059509P | 2009-07-31 | 2009-07-31 | |
| US61/230,595 | 2009-07-31 | ||
| US34644410P | 2010-05-19 | 2010-05-19 | |
| US61/346,444 | 2010-05-19 | ||
| US35102210P | 2010-06-03 | 2010-06-03 | |
| US61/351,022 | 2010-06-03 | ||
| PCT/US2010/043992 WO2011014821A1 (en) | 2009-07-31 | 2010-07-30 | Folate-targeted diagnostics and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012105641A true RU2012105641A (ru) | 2013-09-10 |
Family
ID=43529728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012105641/15A RU2012105641A (ru) | 2009-07-31 | 2010-07-30 | Фолатнацеленные диагностические средства и лечение |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20120128587A1 (enExample) |
| EP (1) | EP2460013A4 (enExample) |
| JP (1) | JP2013501224A (enExample) |
| KR (1) | KR20120050462A (enExample) |
| CN (2) | CN104857534A (enExample) |
| AU (1) | AU2010278734A1 (enExample) |
| BR (1) | BR112012002064A2 (enExample) |
| CA (1) | CA2769754A1 (enExample) |
| IL (1) | IL217744A0 (enExample) |
| IN (1) | IN2012DN01708A (enExample) |
| NZ (1) | NZ598145A (enExample) |
| RU (1) | RU2012105641A (enExample) |
| WO (1) | WO2011014821A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2187965T (pt) | 2007-08-17 | 2020-01-17 | Purdue Research Foundation | Conjugados ligando-ligante de ligação a psma e métodos para utilização |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| WO2012065079A1 (en) | 2010-11-12 | 2012-05-18 | Endocyte, Inc. | Methods of treating cancer |
| CN103607891A (zh) * | 2011-04-12 | 2014-02-26 | 恩多塞特公司 | 固体药用组合物 |
| JP6892218B2 (ja) | 2012-11-15 | 2021-06-23 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 薬物送達結合体およびｐｓｍａ発現細胞によって引き起こされる疾患の治療方法 |
| US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
| JP6595463B2 (ja) | 2013-10-16 | 2019-10-23 | ユニベルシテ リブレ デ ブリュッセル | 気道に影響する増殖性疾患の処置に有用な製剤 |
| EP3415489A1 (en) | 2013-10-18 | 2018-12-19 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| ES2860173T3 (es) | 2013-11-19 | 2021-10-04 | Purdue Research Foundation | Método de selección de pacientes para inflamación |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| US20170368208A1 (en) * | 2015-01-11 | 2017-12-28 | Endocyte, Inc. | Cancer imaging agent |
| IL237525A (en) | 2015-03-03 | 2017-05-29 | Shalom Eli | Method for labeling a prostate-specific membrane antigen with a radioactive isotope |
| WO2018182776A1 (en) * | 2016-03-29 | 2018-10-04 | Endocyte, Inc. | Folate conjugate for use in targeting tumor associated macrophages |
| WO2017192863A1 (en) | 2016-05-04 | 2017-11-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| WO2017205661A1 (en) * | 2016-05-25 | 2017-11-30 | Purdue Research Foundation | Method of treating cancer by targeting myeloid-derived suppressor cells |
| US12208102B2 (en) | 2018-04-17 | 2025-01-28 | Endocyte, Inc. | Methods of treating cancer |
| CN120097930A (zh) | 2019-05-20 | 2025-06-06 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2512867C (en) * | 2003-01-27 | 2014-08-26 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| JP5243041B2 (ja) * | 2004-12-21 | 2013-07-24 | ネクター セラピューティックス | 安定化ポリマーチオール試薬 |
| US20070276231A1 (en) * | 2004-12-23 | 2007-11-29 | Low Philip S | Positron Emission Tomography Imaging Method |
| EP1863816B1 (en) * | 2005-03-16 | 2014-06-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
| AU2006230219A1 (en) * | 2005-03-30 | 2006-10-05 | Endocyte, Inc. | Method for cancer prognosis using cellular folate vitamin receptor quantification |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2010507659A (ja) * | 2006-10-25 | 2010-03-11 | シェーリング コーポレイション | 卵巣癌を処置する方法 |
| RU2523909C2 (ru) * | 2007-06-25 | 2014-07-27 | Эндосайт, Инк. | Конъюгаты, содержащие гидрофильные спейсеры линкеров |
-
2010
- 2010-07-30 NZ NZ598145A patent/NZ598145A/en not_active IP Right Cessation
- 2010-07-30 US US13/388,184 patent/US20120128587A1/en not_active Abandoned
- 2010-07-30 IN IN1708DEN2012 patent/IN2012DN01708A/en unknown
- 2010-07-30 KR KR1020127005358A patent/KR20120050462A/ko not_active Ceased
- 2010-07-30 JP JP2012523104A patent/JP2013501224A/ja active Pending
- 2010-07-30 CN CN201510160314.2A patent/CN104857534A/zh active Pending
- 2010-07-30 WO PCT/US2010/043992 patent/WO2011014821A1/en not_active Ceased
- 2010-07-30 EP EP10805137A patent/EP2460013A4/en not_active Withdrawn
- 2010-07-30 CA CA2769754A patent/CA2769754A1/en not_active Abandoned
- 2010-07-30 BR BR112012002064A patent/BR112012002064A2/pt not_active IP Right Cessation
- 2010-07-30 AU AU2010278734A patent/AU2010278734A1/en not_active Abandoned
- 2010-07-30 RU RU2012105641/15A patent/RU2012105641A/ru not_active Application Discontinuation
- 2010-07-30 CN CN2010800434602A patent/CN102549434A/zh active Pending
-
2012
- 2012-01-26 IL IL217744A patent/IL217744A0/en unknown
-
2013
- 2013-03-13 US US13/800,309 patent/US20140140925A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013501224A (ja) | 2013-01-10 |
| EP2460013A1 (en) | 2012-06-06 |
| US20140140925A1 (en) | 2014-05-22 |
| BR112012002064A2 (pt) | 2017-05-09 |
| AU2010278734A1 (en) | 2012-02-23 |
| WO2011014821A1 (en) | 2011-02-03 |
| KR20120050462A (ko) | 2012-05-18 |
| NZ598145A (en) | 2014-10-31 |
| IN2012DN01708A (enExample) | 2015-06-05 |
| CN102549434A (zh) | 2012-07-04 |
| US20120128587A1 (en) | 2012-05-24 |
| IL217744A0 (en) | 2012-03-29 |
| EP2460013A4 (en) | 2013-04-03 |
| CN104857534A (zh) | 2015-08-26 |
| CA2769754A1 (en) | 2011-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012105641A (ru) | Фолатнацеленные диагностические средства и лечение | |
| Wang et al. | HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib | |
| Shimomura et al. | First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors | |
| Mégalizzi et al. | 4-IBP, a σ1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs | |
| US20250325553A1 (en) | Methods of treating cancer | |
| JP2013501224A5 (enExample) | ||
| Isambert et al. | Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phase | |
| JP2022079545A (ja) | リポソーマルイリノテカンによる乳がんの治療 | |
| Wagner et al. | Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour | |
| Kaartinen et al. | Haemodynamic interactions of medetomidine and the peripheral alpha-2 antagonist MK-467 during step infusions in isoflurane-anaesthetised dogs | |
| Lin et al. | Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer | |
| Novello et al. | Early Response to Chemotherapy in Patients With Non–Small-Cell Lung Cancer Assessed by [18F]-Fluoro-Deoxy-D-Glucose Positron Emission Tomography and Computed Tomography | |
| KR20180082428A (ko) | 성장 호르몬 결핍의 검출 및 치료 | |
| Gilbert et al. | A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck | |
| Maino et al. | Refill procedures of intrathecal drug delivery systems with a recessed fill port on the pump surface: A prospective comparison study of ultrasound-guided vs. blind refill technique | |
| JP2018538370A (ja) | デシタビン、５アザシチジンおよびテトラヒドロウリジンを含有する組成物およびその使用 | |
| JP2021531330A (ja) | 組合せ療法を使用してがんを治療する方法 | |
| CN110638802A (zh) | Atca在制备治疗肿瘤的药物中的用途 | |
| Huang et al. | Toxic myelitis and arachnoiditis after intrathecal delivery of bupivacaine via an implanted drug delivery system: case report and review of the literature | |
| ES3024982T3 (en) | Injection containing p-boronophenylalanine | |
| Sullivan et al. | Treatments for severe psoriasis | |
| Apfelbaum et al. | LGG-02. Elucidating the role of fgfr1 alterations in pediatric gliomas | |
| Goldstein et al. | 4 HMGB1 DETECTION IN PATIENTS WITH CEREBRAL AND MYOCARDIAL ISCHEMIA | |
| Russell et al. | POS1228 IMPACT OF COVID-19 ON THE PRESCRIPTION OF BIOLOGIC DMARDs: A POPULATION-LEVEL STUDY IN ENGLAND | |
| WO2011139867A2 (en) | Method of treating brain cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160126 |